share_log

翰森製藥：截至二零二三年十二月三十一日止年度的年度業績公告

HANSOH PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 26 06:01
Summary by Moomoo AI
翰森制药集团有限公司（「本公司」）公布截至2023年12月31日止年度的年度業績。本公司及其附屬公司（「本集團」）錄得收入約人民幣101.04億元，較上年增長約7.7%；溢利約人民幣32.78億元，增長約26.9%；每股盈利約人民幣0.55元，增長約26.6%。本集團於報告期內獲批上市七款創新藥，並成功轉型為專注於開發和銷售創新藥物的創新型生物製藥公司。報告期內，本集團共有六個新產品獲批上市，包含一款創新藥；新申報及獲得臨床批件二十三件，分屬十個創新藥相關。此外，本公司於報告期內獲得多項國際合作機會，包括與GSK、SCYNEXIS等公司訂立獨家合作協議。本公司亦於報告期內獲得MSCI（明晟）ESG評級提升至AA級，並入選S&P發佈的《可持續發展年鑒（全球版）2024》。董事會建議派發末期股息每股14.22港仙。
翰森制药集团有限公司（「本公司」）公布截至2023年12月31日止年度的年度業績。本公司及其附屬公司（「本集團」）錄得收入約人民幣101.04億元，較上年增長約7.7%；溢利約人民幣32.78億元，增長約26.9%；每股盈利約人民幣0.55元，增長約26.6%。本集團於報告期內獲批上市七款創新藥，並成功轉型為專注於開發和銷售創新藥物的創新型生物製藥公司。報告期內，本集團共有六個新產品獲批上市，包含一款創新藥；新申報及獲得臨床批件二十三件，分屬十個創新藥相關。此外，本公司於報告期內獲得多項國際合作機會，包括與GSK、SCYNEXIS等公司訂立獨家合作協議。本公司亦於報告期內獲得MSCI（明晟）ESG評級提升至AA級，並入選S&P發佈的《可持續發展年鑒（全球版）2024》。董事會建議派發末期股息每股14.22港仙。
Hansen Pharmaceutical Group Limited (the “Company”) announces its annual results for the year ended 31 December 2023. The Company and its subsidiaries (the “Group”) recorded revenues of approximately RMB101.4 billion, an increase of approximately 7.7% year-on-year; profit of approximately RMB378 million, an increase of approximately 26.9%; and earnings per share of approximately RMB0.55, an increase of approximately 26.6%. The Group was approved to market seven innovative medicines during the reporting period and successfully transformed into an innovative biopharmaceutical company focused on the development and sale of innovative medicines. During the reporting period, the Group had a total of six new product approvals, including one innovative drug; 23 new applications and clinical batches, each of which were related to 10 innovative medicines. IN ADDITION, THE COMPANY RECEIVED SEVERAL INTERNATIONAL...Show More
Hansen Pharmaceutical Group Limited (the “Company”) announces its annual results for the year ended 31 December 2023. The Company and its subsidiaries (the “Group”) recorded revenues of approximately RMB101.4 billion, an increase of approximately 7.7% year-on-year; profit of approximately RMB378 million, an increase of approximately 26.9%; and earnings per share of approximately RMB0.55, an increase of approximately 26.6%. The Group was approved to market seven innovative medicines during the reporting period and successfully transformed into an innovative biopharmaceutical company focused on the development and sale of innovative medicines. During the reporting period, the Group had a total of six new product approvals, including one innovative drug; 23 new applications and clinical batches, each of which were related to 10 innovative medicines. IN ADDITION, THE COMPANY RECEIVED SEVERAL INTERNATIONAL COOPERATION OPPORTUNITIES DURING THE REPORTING PERIOD, INCLUDING THE CONCLUSION OF EXCLUSIVE COOPERATION AGREEMENTS WITH COMPANIES SUCH AS GSK, SCYNEXIS. The Company was also upgraded to AA by MSCI (Ming Sheng) ESG during the reporting period and was selected in S&P's Sustainability Yearbook (Global Edition) 2024. The Board of Directors proposes to pay a final dividend of HK14.22 cents per share.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more